Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 10, 2021

Aldeyra concludes enrolment in Phase III dry eye disease treatment trial

The trial will have 300 dry eye disease patients, with ocular redness being the primary goal.

Aldeyra Therapeutics has concluded the subject enrolment in the Phase III TRANQUILITY clinical trial of its experimental therapy, a 0.25% reproxalap ophthalmic solution (reproxalap), to treat people with dry eye disease.

Reproxalap is a new small-molecule immune-modulating covalent inhibitor of reactive aldehyde species.

The double-masked, multicentre parallel-group Phase III trial enrolled 300 subjects, who were categorised to give either reproxalap or a vehicle.

Subjects were given four doses one day before and two doses on the day of their exposure to a 90-minute dry eye chamber with low humidity, increased airflow, and compelled visual tasking.

Ocular redness is the primary goal of the trial with top-line data anticipated in this quarter of the year.

A Phase II trial with 158 subjects achieved statistical significance in the primary goal of ocular redness.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Aldeyra is also carrying out another identical Phase III trial, TRANQUILITY-2, in dry eye disease patients. Enrolment is underway for this trial.

Aldeyra president and CEO Todd Brady said: “Following the recent announcement of top-line results from our Phase II clinical trial, which achieved the primary endpoint of ocular redness, and which we intend to submit as a pivotal trial, completion of enrolment in TRANQUILITY is a significant milestone as we advance reproxalap toward an anticipated NDA submission early next year for the treatment of dry eye disease.

“If the primary endpoint of ocular redness in TRANQUILITY is achieved, and in conjunction with two previously announced clinical trials demonstrating improvement in ocular dryness symptoms, we believe that the efficacy requirements for NDA submission will have been met.”

The company intends to submit the Phase II data, as well as positive Ocular Redness results from the TRANQUILITY trial, to seek New Drug Application (NDA) from the US Food and Drug Administration (FDA) early next year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU